STOCK TITAN
  1. Home
  2. News
  3. KRRO

Korro Bio, Inc. - $KRRO STOCK NEWS

Welcome to our dedicated page for Korro Bio news (Ticker: $KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Korro Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Korro Bio's position in the market.

News
Korro Announces $70 Million Private Placement
Rhea-AI Summary
Korro Bio, Inc. announces a $70 million private placement led by Deep Track Capital and other healthcare investors. The financing is expected to close on April 22, 2024, providing pro-forma cash of approximately $236 million. Korro plans to use the proceeds for regulatory filings, interim readouts, and study completions for its genetic medicines. The company aims to advance its pipeline programs and platform development, with a focus on delivery and machine learning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
-
News
Korro to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Korro Bio, Inc. announces CEO and executives' participation in upcoming investor conferences to discuss progress on KRRO-110, a promising candidate for AATD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.9%
Tags
conferences
-
News
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
Rhea-AI Summary
Korro Bio, Inc. (KRRO) reports strong financials for 2023, with a cash balance of $166 million, anticipating regulatory filing for KRRO-110 in AATD patients in late 2024. The company demonstrated over 50% editing using GalNAc conjugates in a preclinical mouse model and achieved significant milestones in pipeline development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
earnings
News
Korro to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Korro Bio, Inc. (KRRO) announced CEO Ram Aiyar will present at TD Cowen 44th Annual Health Care Conference. CFO and CSO to participate. Webcast available on Korro's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
conferences
-
News
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
Rhea-AI Summary
Korro Bio, Inc. presented new data for KRRO-110 at the J.P. Morgan Healthcare Conference, showcasing its potential as a best-in-class therapeutic for AATD patients. The company reported progress across its RNA editing portfolio, demonstrating high specificity and sustained protein correction in preclinical mouse models. Korro's proprietary RNA editing platform, OPERA™, has shown potential in creating de novo mutations to alter protein function, with promising results in activating transcription factors and modulating ion channels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
none
-
News
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Korro Bio, Inc. (KRRO) announced that CEO Ram Aiyar, Ph.D., will present at the J.P. Morgan Healthcare Conference to discuss new platform data and preclinical data on its development candidate, KRRO-110, for treating Alpha-1 Antitrypsin Deficiency. Preclinical development is ongoing for a potential regulatory filing in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences
News
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Rhea-AI Summary
Korro Bio, Inc. (Nasdaq: KRRO) has nominated its first development candidate, KRRO-110, for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is a proprietary RNA editing oligonucleotide designed to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. The company expects regulatory filing in the second half of 2024. Korro has demonstrated the ability to repair the misfolding of the A1AT protein and reduce liver aggregates in a preclinical mouse model, as well as high editing efficiency leading to increased secretion of normal A1AT protein. AATD is an inherited genetic disorder, and Korro's approach has the potential to be transformative for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.67%
Tags
none
-
News
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
Rhea-AI Summary
Korro Bio, Inc. (KRRO) appoints biotech veteran Rachel Meyers, PhD, to its Board of Directors, bringing over two decades of life science experience. Dr. Meyers' expertise in RNA-based medicines and leadership roles at Faze Medicines and Alnylam Pharmaceuticals will strengthen Korro's RNA editing platform for genetic medicines development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
management
Stock KRRO logo
Korro Bio, Inc.

Nasdaq:KRRO

KRRO Rankings

#3028 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

KRRO Stock Data

485.15M
3.20M
7.53%
81.86%
1.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About KRRO

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.